PROKIDNEY CORP.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $893,000 | $76,000 | $0 | $0 | — |
| Research and development | $114.1M | $127.7M | $106.7M | $82.1M | $46.3M |
| Operating expenses | $165.9M | $183.8M | $151.5M | $153.0M | $55.1M |
| Operating income | -$165.0M | -$183.7M | -$151.5M | -$153.0M | -$55.1M |
| Interest expense | $4,000 | $9,000 | $12,000 | $215,000 | $0 |
| Pretax income | -$151.2M | -$163.9M | -$129.5M | -$147.2M | -$55.1M |
| Income tax expense | $414,000 | -$598,000 | $6.0M | $896,000 | $38,000 |
| Net income | -$69.0M | -$61.2M | -$35.5M | -$148.1M | -$55.1M |
| Balance Sheet | |||||
| Cash and equivalents | $108.5M | $99.1M | $60.6M | $490.3M | $20.6M |
| Current assets | $280.7M | $395.9M | $374.1M | $504.7M | $27.3M |
| Total assets | $335.6M | $441.1M | $420.6M | $518.0M | $40.3M |
| Current liabilities | $30.7M | $36.2M | $25.0M | $10.9M | $12.3M |
| Total liabilities | $34.8M | $39.4M | $29.2M | $13.1M | $13.4M |
| Stockholders' equity | -$1.0B | -$995.0M | -$1.1B | -$1.1B | $26.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$120.1M | -$126.4M | -$90.1M | -$77.1M | -$50.3M |
| Depreciation and amortization | $6.6M | $5.4M | $3.9M | $3.0M | $2.0M |
| Stock-based compensation | $25.3M | $29.4M | $30.8M | $74.5M | $699,000 |
| Capital expenditure | $15.2M | $29.5M | $34.2M | $1.8M | $5.2M |
| Free cash flow | -$135.3M | -$155.9M | -$124.3M | -$78.9M | -$55.5M |
| Share repurchases | $0 | $0 | $9.5M | $0 | $0 |
| Impairments | $318,000 | $5.3M | $0 | $0 | — |
Shares outstanding 302.1M
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.